Mutations of the p53 gene and loss of heterozygosity at chromosome 17p13.1 are associated with increased survivin expression in breast cancer

Breast Cancer Research and Treatment
Naoki TsujiNaoki Watanabe

Abstract

Expression of survivin, a member of the inhibitor-of-apoptosis (IAP) family, is elevated in fetal tissues and in various human cancers originating in the breast, lung, prostate, colon, pancreas, and stomach. Since overexpression of the survivin gene has been linked to poor patient survival in several cancers, survivin may be an important prognostic marker. Mechanisms up-regulating survivin gene expression in cancer are poorly understood. Recently, wild-type p53 was found to repress expression of the survivin gene by binding to the survivin promoter, thereby inhibiting promoter activity. Further, loss of heterozygosity (LOH) at 17p13 distal to the p53 gene is associated with more aggressive behavior of breast cancers. We therefore tested the hypothesis that not only p53 gene mutation but also LOH at 17p13 can up-regulate survivin expression in breast cancer. Survivin mRNA expression was greater in cancers than in uninvolved tissues (p < 0.0001). Mutations of the p53 gene were detected in 5 of 25 tumors; higher survivin gene expression was evident in these. LOH at the D17S938 locus (17p13.1) was found in 10 of 25 tumors, and most of these also showed increased survivin gene expression. Thus expression of survivin may be regulated...Continue Reading

References

Aug 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·P M HollandD H Gelfand
May 15, 1997·Nature·Y HauptM Oren
Aug 1, 1997·Nature Medicine·G AmbrosiniD C Altieri
Mar 30, 1999·Experimental Cell Research·M Jäättelä
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MonzóA Abad
Nov 24, 1999·The American Journal of Medicine·P SaikumarM A Venkatachalam
Nov 28, 2000·Japanese Journal of Cancer Research : Gann·K AsanumaN Watanabe
Nov 21, 2001·The Journal of Biological Chemistry·William H HoffmanMaureen Murphy

❮ Previous
Next ❯

Citations

Oct 21, 2005·The Journal of Molecular Diagnostics : JMD·Matthias WoenckhausWolfgang Dietmaier
Jan 30, 2008·Applied Immunohistochemistry & Molecular Morphology : AIMM·Aziza NassarCynthia Cohen
Feb 28, 2008·Applied Immunohistochemistry & Molecular Morphology : AIMM·Aziza NassarCynthia Cohen
May 19, 2010·Biomarkers in Medicine·Hirendra Nath Banerjee, Mukesh Verma
Oct 22, 2011·International Journal of Molecular Sciences·Wei Zhang, Yingyan Yu
Feb 22, 2011·Surgical Oncology·Kumkum JhaManoj Pandey
Jan 23, 2008·American Journal of Clinical Pathology·Samia GonzalezXavier Leroy
Aug 26, 2016·Breast Cancer : Basic and Clinical Research·David N Danforth
Jul 11, 2007·Molecular Cancer Therapeutics·Ellen WeisbergJames D Griffin
Jan 13, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B M RyanM J Duffy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban
Wanguang ZhangFazu Qiu
Clinica Chimica Acta; International Journal of Clinical Chemistry
Atsuhito YagihashiNaoki Watanabe
© 2021 Meta ULC. All rights reserved